Capricor Therapeutics (NASDAQ:CAPR) Stock Bounces Back After The Fall: What Next?

The biotech firm Capricor Therapeutics (NASDAQ:CAPR) was on the radars of many investors yesterday and the company’s stock ended the day with gains of 5.5%. The gains made by the Capricor stock were reasonable but it is also true that there has been no new development about the company in recent weeks.

In this situation, it might be useful for investors to remember that back on June 17 the company had announced that its Chief Executive Officer Linda Marban was going to provide an update regarding the recent findings that had been made by Capricor at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference.

In addition to that, Marban was also going to provide a preliminary review regarding the Phase II Hope 2 trial as part of an open label extension study into its lead candidate CAP 1002. The company’s CEO participated at a panel that was held on June 23 and discussed a range of therapies during the panel discussion called ‘In the Pipeline Protecting the Muscle’.

However, is should be noted that it is unlikely that the latest rally was related to the presentation made around a month ago. Hence, it might be a good idea for investors to keep an eye out for any news regarding Capricor this week.

Market Reaction:

On Monday, CAPR stock gained 5.31% at $4.56 with more than 158k shares, compared to its average volume of 561K shares. The stock has moved within a range of $4.2157 – 4.6000 after opening the trade at $4.30. Over the past 52-week, the stock has been trading within a range of $3.1300 – 12.3200.